Factors Associated With Decision Making In the Second-Line Treatment of Patients With Advanced/Metastatic Gastrointestinal Cancers
Podcast 3: Advances in anti-angiogenic treatment for GEJ cancers with clinical trials

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Edith is a 71 year-old woman with HER2- gastric cancer and diffuse nodal metastases whose cancer has progressed despite being on FOLFOX/nivolumab therapy. She is interested in enrolling in a clinical trial. What factors should she consider before pursuing further treatment?
Edith is interested in a trial looking at combining anti-VEGF treatment options. What information can you give her regarding anti-VEGF use in second-line therapy?
Powered by QuestionPro